Oxford BioTherapeutics’ Post

Interesting new publication in #NatureBiotechnology where the #EuropeanInnovationCouncil (EIC) outlines their investment strategy focusing on innovative biomarkers to personalize cancer treatment and DoMore Diagnostics being showcased as one of their main investments. The author describes the #EIC “…as potentially the most effective catalyst of breakthrough science to disruptive innovation, the EIC has the objective of creating an ecosystem that fosters deeptech science-based businesses by harnessing European research and development efforts, unblocking innovative potential in Europe.” #digitalpathology #precisionmedicine #precisiononcology #cancer #aiinhealth #colorectalcancer #coloncancer #personalizedmedicine Link to the article (paid access): https://lnkd.in/dsd5z-6w

"If someone you know to be thoughtful and rational makes a very different decision than you might under the same circumstance, it’s probably worthwhile to ask what time horizon they are operating under as that might be the root distinction." More than a biotech billionaire, Bob Duggan, CEO of Summit Therapeutics, Inc. has changed and is continuing to change lives. Born out of the death of his son from brain cancer, his dedication to biotech coupled with "intensity to learn and get things right" is admirable. #longtermview #patientcapital #biotech #lifesciences https://lnkd.in/daiV8gUp

Exploring Strategic Growth: Cizzle Biotechnology's 2023 Annual Report We are excited to share insights from Cizzle Biotechnology Holdings plc's 2023 Annual Report, which highlights a year of strategic partnerships and advancements in lung cancer detection technologies. Dive into the details of their financial performance, strategic licensing initiatives, and the steps they're taking towards minimizing environmental impact. Discover how these initiatives align with our mission to innovate in healthcare and what lies ahead for Cizzle Biotechnology. 🔗 Read the full summary on our blog: https://buff.ly/4f6vShk #CizzleBiotechnology #AnnualReport #LungCancerAwareness #HealthcareInnovation

Topics include: Tabloids and Cancer, Momentum in Biotech- Reversion to the Mean, Follow-On Investing and the Q2 2024 Biotech Outlook #theDoctorisIN #wealthmanagement #financialadvisors #pharma

The American Association for Cancer Research's 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟰 is approaching, and my colleagues Renee Vaughn and Bill Leone will attend in San Diego with industry peers from around the US. If you are planning an #Oncology #ClinicalTrial and want to know that it is in good hands from start to finish, arrange a meeting with my colleagues. #conference #meeting #AACR2024 #MakeADifference #Pharma #Biotech #CancerResearch #ClinicalResearch

Full presentation on how to heal multifactorial diseases with one bacteria:

Celldex is leading the science at the intersection of mast cell biology and the development of transformative #antibody therapeutics to improve the lives of patients. In our new series, Talking with Tibor, Celldex Co-founder and Chief Scientific Officer Tibor Keler, Ph.D. will take us through the basics of antibody therapeutics, mast cells and more, to break down how Celldex's approach is uniquely different. Listen in to the first episode below. 

Twenty three companies will share from £12 million in funding that has been awarded to advance innovative cancer projects and will be shared by 16 projects led by small and medium-sized enterprises at various stages right from feasibility through to regulatory approval. They include industry-led research and development projects by Antikor Biopharma Ltd, Cell Guidance Systems, Coding Bio, Epitopea, Grey Wolf Therapeutics, Lentitek, Medannex Ltd, Mestag Therapeutics, Momentous Therapeutics Ltd, Pathios Therapeutics, Prokarium, QV Bioelectronics, Revolver Therapeutics, #Sferola, Theolytics, VacV Biotherapeutics Feasibility project by CREASALLIS, Galytx, Kargenera, New Path Molecular Research, #OligoTune, Proteotype Diagnostics & Xgenera Congratulations to you all and we look forward to hearing more about the results Find out more via UK Research and Innovation https://lnkd.in/eg5RsCu8 #CancerResearch #InnovationInHealthcare #SmallBusinessGrants #MedicalInnovation #HealthTech #ClinicalTrials #BiotechFunding #HealthcareInnovation #SMEFunding #ResearchAndDevelopment

ROTH Capital Partners (ROTH MKM) rates Imugene Limited (ASX:IMU) as a 'Buy' with a 12-month price target of AUD$0.42. As they advance their innovative cancer therapies and ensure financial stability until 2026, Imugene stands out in the biotech sector. #Biotech #Imugene #IMU #companyresearch #researchreport #InvestmentOpportunity #cancer #cancerresearch

The number of ADCs showing promising outcomes in clinical trials is rapidly growing, offering exciting opportunities for cancer patients. The inaugural Engineering Conjugates conference ( https://lnkd.in/egpzyeYZ) at #PEGSEurope brings leaders in the field together to share innovations in next-gen #ADC formats to enhance #payload delivery and improve #therapeuticindex. Hear progress in bispecific ADCs, peptide/fragment-based ADCs, dual-payloads, novel targets such as Nectin-4, CEACAM5C and more! Speakers include: Yves BAUDAT, Sanofi Ulrich Brinkmann, Roche Innovation Center Munich Jutta Deckert, Iksuda Therapeutics Mahendra Deonarain, Antikor Biopharma Nimish Gera, Mythic Therapeutics Kim Holmstrøm, Bioneer AS Ilias Koutsopetras, University of Strasbourg Sara Mangsbo, Uppsala University Diane Retallack, Primrose Bio Min Shan 单旻, Merck KGaA Caroline Soulas, Innate Pharma Philipp Spycher, Araris Biotech Ralf Strasser, Bruker Biosensors Obinna C Ubah, Elasmogen Ltd Sandra Uhlenbroich, Bicycle Therapeutics #proteinengineering #Antibodydrugconjugates #noveltargets